Nakashima R, Hosono Y, Mimori T. Clinical significance and new detection system of autoantibodies in myositis with interstitial lung disease. Lupus. 2016;25(8):925–33.

Article  CAS  PubMed  Google Scholar 

Lin RR, Warp PV, Maderal AD, Elman SA. Assessing time of onset for interstitial lung disease in Anti-MDA5 Antibody-Positive dermatomyositis. JAMA Dermatol. 2024;160(5):575–7.

Article  PubMed  PubMed Central  Google Scholar 

Betteridge Z, Tansley S, Shaddick G, Chinoy H, Cooper RG, New RP, et al. Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients. J Autoimmun. 2019;101:48–55.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nombel A, Fabien N, Coutant F. Dermatomyositis with Anti-MDA5 antibodies: bioclinical features, pathogenesis and emerging therapies. Front Immunol. 2021;12:773352.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nakashima R, Imura Y, Kobayashi S, Yukawa N, Yoshifuji H, Nojima T, et al. The RIG-I-like receptor IFIH1/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody. Rheumatology (Oxford). 2010;49(3):433–40.

Article  CAS  PubMed  Google Scholar 

Muro Y, Sugiura K, Hoshino K, Akiyama M, Tamakoshi K. Epidemiologic study of clinically amyopathic dermatomyositis and anti-melanoma differentiation-associated gene 5 antibodies in central Japan. Arthritis Res Ther. 2011;13(6):R214.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Koga T, Fujikawa K, Horai Y, Okada A, Kawashiri SY, Iwamoto N, et al. The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM. Rheumatology (Oxford). 2012;51(7):1278–84.

Article  CAS  PubMed  Google Scholar 

Sato S, Hirakata M, Kuwana M, Suwa A, Inada S, Mimori T, et al. Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum. 2005;52(5):1571–6.

Article  CAS  PubMed  Google Scholar 

Ceribelli A, Fredi M, Taraborelli M, Cavazzana I, Tincani A, Selmi C, et al. Prevalence and clinical significance of anti-MDA5 antibodies in European patients with polymyositis/dermatomyositis. Clin Exp Rheumatol. 2014;32(6):891–7.

PubMed  Google Scholar 

Fujikawa K, Kawakami A, Kaji K, Fujimoto M, Kawashiri S, Iwamoto N, et al. Association of distinct clinical subsets with myositis-specific autoantibodies towards anti-155/140-kDa polypeptides, anti-140-kDa polypeptides, and anti-aminoacyl tRNA synthetases in Japanese patients with dermatomyositis: a single-centre, cross-sectional study. Scand J Rheumatol. 2009;38(4):263–7.

Article  CAS  PubMed  Google Scholar 

Fiorentino D, Chung L, Zwerner J, Rosen A, Casciola-Rosen L. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J Am Acad Dermatol. 2011;65(1):25–34.

Article  PubMed  PubMed Central  Google Scholar 

Labrador-Horrillo M, Martinez MA, Selva-O’Callaghan A, Trallero-Araguas E, Balada E, Vilardell-Tarres M, et al. Anti-MDA5 antibodies in a large mediterranean population of adults with dermatomyositis. J Immunol Res. 2014;2014:290797.

Article  PubMed  PubMed Central  Google Scholar 

Gono T, Kawaguchi Y, Kuwana M, Sugiura T, Furuya T, Takagi K, et al. Brief report: association of HLA-DRB1*0101/*0405 with susceptibility to anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis in the Japanese population. Arthritis Rheum. 2012;64(11):3736–40.

Article  CAS  PubMed  Google Scholar 

Rothwell S, Chinoy H, Lamb JA, Miller FW, Rider LG, Wedderburn LR, et al. Focused HLA analysis in Caucasians with myositis identifies significant associations with autoantibody subgroups. Ann Rheum Dis. 2019;78(7):996–1002.

Article  CAS  PubMed  Google Scholar 

Kochi Y, Kamatani Y, Kondo Y, Suzuki A, Kawakami E, Hiwa R, et al. Splicing variant of WDFY4 augments MDA5 signalling and the risk of clinically amyopathic dermatomyositis. Ann Rheum Dis. 2018;77(4):602–11.

Article  CAS  PubMed  Google Scholar 

Guo L, Zhang X, Pu W, Zhao J, Wang K, Zhang D, et al. WDFY4 polymorphisms in Chinese patients with anti-MDA5 dermatomyositis is associated with rapid progressive interstitial lung disease. Rheumatology (Oxford). 2023;62(6):2320–4.

Article  CAS  PubMed  Google Scholar 

Theisen DJ, Davidson JT, Briseño CG, Gargaro M, Lauron EJ, Wang Q, et al. WDFY4 is required for cross-presentation in response to viral and tumor antigens. Science. 2018;362(6415):694–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li Y, Li J, Yuan Q, Bian X, Long F, Duan R, et al. Deficiency in WDFY4 reduces the number of CD8 + T cells via reactive oxygen species-induced apoptosis. Mol Immunol. 2021;139:131–8.

Article  CAS  PubMed  Google Scholar 

Chen Z, Cao M, Plana MN, Liang J, Cai H, Kuwana M, et al. Utility of anti-melanoma differentiation-associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta-analysis. Arthritis Care Res (Hoboken). 2013;65(8):1316–24.

Article  CAS  PubMed  Google Scholar 

Nishina N, Sato S, Masui K, Gono T, Kuwana M. Seasonal and residential clustering at disease onset of anti-MDA5-associated interstitial lung disease. RMD Open. 2020;6(2):e001202.

Article  PubMed  PubMed Central  Google Scholar 

Toquet S, Granger B, Uzunhan Y, Mariampillai K, Nunes H, Benveniste O, et al. The seasonality of dermatomyositis associated with anti-MDA5 antibody: an argument for a respiratory viral trigger. Autoimmun Rev. 2021;20(4):102788.

Article  CAS  PubMed  Google Scholar 

Palterer B, Mazzoni A, Infantino M, Semeraro R, Manfredi M, Pesce G, et al. Seasonal patterns of myositis-specific and myositis-associated autoantibodies in Italy: seasonal patterns of myositis autoantibodies. Immunol Lett. 2024;272:106966.

Article  PubMed  Google Scholar 

So H, So J, Lam TTO, Wong VTL, Ho R, Li WL, et al. Seasonal effect on disease onset and presentation in Anti-MDA5 positive dermatomyositis. Front Med (Lausanne). 2022;9:837024.

Article  PubMed  Google Scholar 

Kang Dchul, Gopalkrishnan RV, Wu Q, Jankowsky E, Pyle AM, Fisher PB. mda-5: an interferon-inducible putative RNA helicase with double-stranded RNA-dependent ATPase activity and melanoma growth-suppressive properties. Proc Natl Acad Sci U S A. 2002;99(2):637–42.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kang DC, Gopalkrishnan RV, Lin L, Randolph A, Valerie K, Pestka S, et al. Expression analysis and genomic characterization of human melanoma differentiation associated gene-5, mda-5: a novel type I interferon-responsive apoptosis-inducing gene. Oncogene. 2004;23(9):1789–800.

Article  CAS  PubMed  Google Scholar 

Zahn S, Barchet W, Rehkämper C, Hornung T, Bieber T, Tüting T, et al. Enhanced skin expression of melanoma differentiation-associated gene 5 (MDA5) in dermatomyositis and related autoimmune diseases. J Am Acad Dermatol. 2011;64(5):988–9.

Article  PubMed  Google Scholar 

Gono T, Okazaki Y, Kuwana M. Antiviral Proinflammatory phenotype of monocytes in anti-MDA5 antibody-associated interstitial lung disease. Rheumatology (Oxford). 2022;61(2):806–14.

Article  CAS  PubMed  Google Scholar 

Liu Y, Feng S, Liu X, Tang Y, Li X, Luo C, et al. IFN-beta and EIF2AK2 are potential biomarkers for interstitial lung disease in anti-MDA5 positive dermatomyositis. Rheumatology (Oxford). 2023;62(11):3724–31.

Article  CAS  PubMed  Google Scholar 

Jayaraman S, Tiniakou E, Morgenlander WR, Na M, Christopher-Stine L, Larman HB. Comprehensive enteroviral serology links infection and Anti-Melanoma Differentiation-Associated protein 5 dermatomyositis. ACR Open Rheumatol; 2024.

Castellini C, Scotti C, Navarini L, Fu Q, Qian J, Giacomelli R, et al. The evaluation of type I interferon score in dermatomyositis, a systematic review and a meta-analysis. Autoimmun Rev. 2024;23(12):103686.

Article  CAS  PubMed